Difference and clinical significance of serum GP73 between alcoholic liver disease and non-alcohol fatty liver disease

Aiguo Zhou, Jun Hou, Xin Feng, Yubo Huang, Boan LiChinese 2017 · DOI

Abstract

Objective The present study was designed to evaluate the clinical significance of serum GP73 in patients with alcohol liver disease. Methods Thirty-two patients with alcoholic liver disease (ALD), 40 patients with non-alcohol fatty liver disease(NFLAD), and 40 apparently healthy individuals were included in this study. Results Compared with Those of healthy control population(43.91±19.02 ng/ml), the serum GP73 levels in ALD patients(93.39±66.91 ng/ml) were significantly increased, and also markedly higher than those of NFLAD patients (55.38±21.00 ng/ml). Taken the NFALD ashealthy controls population, and ALD population aspatients , the GP73 may be used to differentiate the ALD from NFLAD. The area of ROC analysis was 0.66(95%CI: 0.52~0.80, P=0.02). We set 75.65 ng/ml as the cut-off value for ALD diagnosis, the sensitivity and specificity were 50.0% and 85.0% respectively. Conclusion Serum GP73 levels in ALD patients were significantly higher than those of NFALD patients. GP73 may be a new marker for differentiating ALD from NFALD. Key words: Alcoholic liver disease; Non-alcohol fatty liver disease; Golgi protein 73; Differentiating diagnosis
BibTeX
@inproceedings{zhou2017difference,
  author = {Aiguo Zhou and Jun Hou and Xin Feng and Yubo Huang and Boan Li},
  title = {{Difference and clinical significance of serum GP73 between alcoholic liver disease and non-alcohol fatty liver disease}},
  booktitle = {Chinese},
  year = {2017},
  doi = {10.3760/cma.j.issn.1003-9279.2017.02.017},
}

Loading related content...

Figure